Dielectric qualities of erythrocytes in healthy people and in patients with cardiovascular disease

2007 ◽  
pp. 733-734
Author(s):  
Y.M. Bobylev
Keyword(s):  
Cardiovascular Disease ◽  
Healthy People

scholarly journals Conventional risk factors and arterial bed parameters in patients with coronary artery disease younger and older than 50 years

2020 ◽  
Vol 19 (4) ◽  
pp. 2541
Author(s):  
A. A. Khromova ◽  
L. I. Salyamova ◽  
O. G. Kvasova ◽  
V. E. Oleinikov
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Healthy People ◽  
Stiffness Index ◽  
Non Invasive ◽  
History Of ◽  
Artery Disease ◽  
Conventional Risk Factors

Aim. To study conventional risk factors and arterial stiffness parameters to identify non-invasive markers of coronary atherosclerosis in patients with and without history of cardiovascular disease, with premature and physiological vascular aging.Material and methods. The study included 198 patients with coronary artery disease (CAD) and 57 healthy people. The subjects were divided into two cohorts: younger and older than 50 years. Each group included patients with newly diagnosed acute coronary syndrome with/without history of cardiovascular disease (CAD and/or hypertension). Conventional risk factors were analyzed in all subjects. Ultrasound radiofrequency of common carotid arteries (CCA), applanation tonometry, volume sphygmography were performed.Results. Analysis of arterial parameters in individuals <50 years old revealed differences between healthy people and patients with CAD. In the subgroup of patients without a history of cardiovascular disease compared with healthy people, CCA were damaged in  77%  (p<0,05), aorta — in 13%, muscular arteries — in 29% (p<0,05); in patients with a history of cardiovascular disease, in 71% (p<0,05), 5% and 34% (p<0,05), respectively. In the older age group of patients with and without history of cardiovascular disease, CCA were damaged in 84% and 94% (p<0,05), aorta — in 92% and 87% (p<0,05), muscular arteries — in 42-44% (p<0,05), respectively. According to the ROC analysis, in patients <50 years old, the area under the curve (AUC) for the intima-media thickness (IMT) was 0,830, the threshold — 622,3 (p=0,000); for the  beta  stiffness index — 0,850, threshold — 7,01 (p=0,002); for L-/CAVI1 — 0,742, threshold — 7,3 (p=0,000). In patients >50 years of age, AUC for the IMT was 0,948, threshold — 607,5 (p=0,000); for the beta stiffness index — 0,740, threshold — 8,84 (p=0,000); for L-/CAVI1 — 0,861, threshold — 8,4 (p=0,000).Conclusion. Timely identification of atherosclerotic markers using noninvasive techniques can improve the prediction of cardiovascular events. A comprehensive non-invasive examination of the arteries with determination of IMT, beta stiffness index, and L-/CAVI1 will probably identify young people with an unfavorable absolute cardiovascular risk. .

scholarly journals Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people

2019 ◽  
Vol 41 (11) ◽  
pp. 1190-1199 ◽  
Author(s):  
Nicole E M Jaspers ◽  
Michael J Blaha ◽  
Kunihiro Matsushita ◽  
Yvonne T van der Schouw ◽  
Nicholas J Wareham ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Smoking Cessation ◽  
Antithrombotic Therapy ◽  
Preventive Therapy ◽  
Healthy People ◽  
Blood Pressure Lowering ◽  
Individual Level ◽  
Pressure Lowering ◽  
Apparently Healthy

Abstract Aims The benefit an individual can expect from preventive therapy varies based on risk-factor burden, competing risks, and treatment duration. We developed and validated the LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model for the estimation of individual-level 10 years and lifetime treatment-effects of cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Methods and results Model development was conducted in the Multi-Ethnic Study of Atherosclerosis (n = 6715) using clinical predictors. The model consists of two complementary Fine and Gray competing-risk adjusted left-truncated subdistribution hazard functions: one for hard cardiovascular disease (CVD)-events, and one for non-CVD mortality. Therapy-effects were estimated by combining the functions with hazard ratios from preventive therapy trials. External validation was performed in the Atherosclerosis Risk in Communities (n = 9250), Heinz Nixdorf Recall (n = 4177), and the European Prospective Investigation into Cancer and Nutrition-Netherlands (n = 25 833), and Norfolk (n = 23 548) studies. Calibration of the LIFE-CVD model was good and c-statistics were 0.67–0.76. The output enables the comparison of short-term vs. long-term therapy-benefit. In two people aged 45 and 70 with otherwise identical risk-factors, the older patient has a greater 10-year absolute risk reduction (11.3% vs. 1.0%) but a smaller gain in life-years free of CVD (3.4 vs. 4.5 years) from the same therapy. The model was developed into an interactive online calculator available via www.U-Prevent.com. Conclusion The model can accurately estimate individual-level prognosis and treatment-effects in terms of improved 10-year risk, lifetime risk, and life-expectancy free of CVD. The model is easily accessible and can be used to facilitate personalized-medicine and doctor–patient communication.

scholarly journals An Exploration the Risk of Cardiovascular Disease in HIV-Positive Persons in Indonesia using Heart Rate Variability

2019 ◽  
Vol 7 (3) ◽  
Author(s):  
Linlin Lindayani ◽  
Irma Darmawati ◽  
Heni Purnama ◽  
Pujowati Pujowati ◽  
Taryudi Taryudi
Keyword(s):  
Cardiovascular Disease ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Heart Disease ◽  
Preventive Measure ◽  
Time Domain Analysis ◽  
Healthy People ◽  
Inclusion Criteria ◽  
Hiv Patients ◽  
The Mean

Cardiovascular disease is the highest cause of death in HIV patients compared to the general population. The number of HIV patients suffering from cardiovascular disease is almost twice as high as patients who are not HIV-positive.The purpose of this study was to identify the risk of cardivascular disease in patients with HIV using ECG short term. This study was used a descriptive comparative to patients with HIV and healthy people as controls in West Java. The inclusion criteria are patients with HIV over the age of 30 years. The exclusion criteria were people with HIV diagnosed with heart disease or being treated for the heart disease. While the inclusion criteria for healthy people as controls are over 30 years of age, do not suffer from cardivascular disease or under treatment of cardiovascular disease. The measurement of heart rate variability is carried out in a supine position in a quiet temperature-controlled room (25-270 C), a 5-minute electrocardiograph (ECG) is recorded using lead II. Differences of heart rate variability indicator were measure using man-whitney test. A total of 20 patients with HIV and 20 healthy people recruited using convinience sampling. The majority of people with HIV were male and aged range between 27 to 51 years old. The results of heart rate variability based on time domain analysis showed that the means normal to normal (NN) was significantly lower in HIV patients compared to controls (978 vs ?? vs 902 ms; p<0.05). No differences were found between groups regarding Standard deviation of NN (SDNN), Square root of the mean squared difference of successive NN-intervals (RMSSD) and Percent of differences between adjacent NN intervals greater than 50 ms (pNN50). This study presence of autonomic dysfunction as showed in heart rate variability indicator in a group of HIV compared to the healthy group. Eearly identification of the risk of CVD is important and may inform the implementation of preventive measure by identification of high-risk people who may be candidate for intervention.

scholarly journals An update to the LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model for prediction of individualized lifetime benefit from cardiovascular risk factor management in apparently healthy people

2021 ◽  
Author(s):  
Tamar I. de Vries ◽  
Nicole E.M. Jaspers ◽  
Frank L.J. Visseren ◽  
Jannick A.N. Dorresteijn
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Life Expectancy ◽  
Cardiovascular Risk Factor ◽  
Treatment Effects ◽  
Original Model ◽  
Healthy People ◽  
Age Range ◽  
Apparently Healthy

Introduction The previously developed LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model can be used to predict lifetime cardiovascular disease risk, CVD-free life expectancy, and lifetime benefit from cardiovascular risk factor treatment in apparently healthy people aged 45 to 80 years. However, there was an unmet need to be able to apply the model in patients younger than 45 years, and to accurately estimate treatment effects in patients with a life expectancy exceeding 90 years. Aim Update the LIFE-CVD model to enable application of the model in people aged 35 to 89 years, and to allow more accurate estimation of treatment effects in patients with a life expectancy exceeding 90 years. Methods The study was conducted using data from the same studies as were used for derivation and validation of the original model, including the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, Atherosclerosis Risk in Communities Study (ARIC) cohort, and the European Prospective Investigation into Cancer-Netherlands (EPIC-NL) and EPIC-Norfolk cohort studies. Age-specific baseline survivals were smoothed by predicting the progression of baseline survivals with age, using a local polynomial regression function and a exponential function for CVD, and non-CVD mortality baseline survivals respectively. Using these functions, baseline survivals were then extrapolated to the age range of 35 to 100 years. External validation using the newly updated baseline survivals was performed. Results Performance of the updated model was not dissimilar from the original model, with C-statistics for discrimination ranging from 0.70-0.76 in the external study populations. Calibration plots showed a good agreement between predicted and observed 10-year CVD risks. Estimation of treatment effects in patients with a life expectancy exceeding 90 years was improved. Conclusion This update of the LIFE-CVD model improves the clinical usability of the model by increasing the age range and improving the method of estimation of lifetime treatment effects.

scholarly journals T Helper Cell Polarization in Healthy People: Implications for Cardiovascular Disease

2013 ◽  
Vol 6 (5) ◽  
pp. 772-786 ◽  
Author(s):  
Nels C. Olson ◽  
Reem Sallam ◽  
Margaret F. Doyle ◽  
Russell P. Tracy ◽  
Sally A. Huber
Keyword(s):  
Cardiovascular Disease ◽  
Cell Polarization ◽  
Healthy People ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper
Sign in / Sign up

Export Citation Format

Share Document